Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Fiche publication
Date publication
novembre 2021
Journal
European journal of heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, Friede T, Göhring UM, Kosiborod MN, Lund LH, Metra M, Quinn CM, Piña IL, Pinto FJ, Rossignol P, Szecsödy P, der Meer PV, Weir M, Pitt B
Lien Pubmed
Résumé
In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K ) binder, may improve serum K levels and adherence to RAASi.
Mots clés
adherence, heart failure, hyperkalaemia, mineralocorticoid receptor antagonists, patiromer, potassium, renin-angiotensin-aldosterone system inhibitors, trial design
Référence
Eur J Heart Fail. 2021 Nov 20;: